LifeMD Q2 2026 earnings: GLP-1 transition widens losses despite margin gains

LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3 million, down from $49.0 million a year earlier, while diluted loss per share from continuing operations widened to $0.16 from $0.09. Gross margin improved to approximately 89%, but higher acquisition spending and lower upfront collections pushed adjusted EBITDA from a profit to a loss.

Core earnings data

Revenue decreased approximately 3.5% as LifeMD continued moving weight-management patients from compounded to branded GLP-1 therapies and changed its pricing and membership mix. Gross profit remained nearly flat despite the lower revenue, supported by reduced shipping and fulfillment costs and the continued scaling of the company’s in-house pharmacy.

The more significant deterioration occurred below gross profit. Operating expenses increased, adjusted EBITDA turned negative, and operating cash flow moved from positive to negative. Comparisons are based on continuing operations and exclude WorkSimpli, which was divested in November 2025.

Subscriber growth and the shift to branded therapies

LifeMD ended the quarter with approximately 356,000 active subscribers, an increase of 20% year over year. Weight Management Program subscribers reached approximately 108,000, compared with just under 100,000 at the end of Q1 2026. Recurring subscriptions generated approximately 84% of total revenue.

The composition of the weight-management business changed substantially. Approximately 95% of new patients now begin treatment with branded GLP-1 therapies, and LifeMD believes its transition away from compounded GLP-1 medications is effectively complete. This shift reduced near-term revenue and profitability because branded therapies and the company’s pricing changes generated less upfront revenue and cash collection.

LifeMD is attempting to offset that pressure by extending membership duration. Following its pricing change, the proportion of new weight-management patients selecting multi-month packages rose from approximately 25% before the change to approximately 85% afterward. Management expects longer subscriptions to improve retention, lifetime value, and revenue predictability, although the quarter’s results primarily reflected the transition costs.

Women’s Health trends also improved through lower customer acquisition costs, according to the company. LifeMD plans to launch additional pharmacy products during the second half and has started an exclusive telehealth co-marketing collaboration with Antares Pharma for XYOSTED, a once-weekly testosterone auto-injector.

Higher gross margin did not offset acquisition spending

LifeMD’s gross margin expanded by approximately 280 basis points even as revenue declined. Lower shipping and fulfillment costs, better provider efficiency, and the scaling of its affiliated pharmacy allowed the company to retain nearly the same gross profit on a smaller revenue base.

However, total operating expenses increased to $49.1 million from $44.5 million. Selling and marketing expense rose 27% year over year to $28.0 million, reflecting elevated customer acquisition costs earlier in the quarter. That increase more than offset a 5% reduction in general and administrative expense to $13.6 million.

Marketing spending did decline by $1.8 million from Q1 as LifeMD implemented its planned reduction in patient-acquisition investment. Management also attributed the adjusted EBITDA loss to lower upfront cash collection associated with the company’s $39 introductory offer, while noting that monthly performance improved as the quarter progressed.

Cash flow and balance sheet

Operating activities from continuing operations used $6.9 million of cash in Q2, compared with $6.1 million generated a year earlier. Working-capital movements included a $3.5 million reduction in accounts payable, a $1.4 million increase in accounts receivable, and a $1.2 million reduction in deferred revenue during the quarter.

LifeMD ended June with $25.1 million in cash, down from $36.8 million at the end of 2025. The company had no debt and maintained an undrawn $30 million revolving credit facility. Management expects cash to begin building through year-end as marketing spending declines and recurring subscriptions increase, making execution on those assumptions important to the liquidity outlook.

Financial guidance

LifeMD substantially reduced its full-year outlook to reflect the GLP-1 transition, pricing and mix changes, and $2 million to $3 million of expected net launch costs for XYOSTED. The updated adjusted EBITDA range now extends from a loss to breakeven, compared with the previously expected profit.

For Q3, LifeMD expects revenue of $48 million to $51 million and adjusted EBITDA ranging from a $1 million loss to a $2 million profit. Management tied the expected profitability improvement to cost savings and continued growth in the recurring rebill base.

Q4 guidance calls for revenue of $60 million to $64 million and adjusted EBITDA of $3 million to $6 million. The company said this implies an annualized exit revenue run rate of approximately $250 million and, before estimated XYOSTED launch costs, approximately $22 million of annualized adjusted EBITDA. These run-rate figures annualize expected Q4 performance and are not full-year 2026 results.

Risks investors should monitor

• Execution against the revised outlook: The sharp reduction in full-year revenue and adjusted EBITDA guidance shows that the branded GLP-1 transition had a larger near-term effect than management initially anticipated. Reaching the Q4 ranges requires meaningful improvement from Q2.
• Unproven economics of longer subscriptions: LifeMD expects multi-month plans to improve retention and lifetime value, but the quarter already reflected lower upfront revenue and cash collection from its pricing and mix decisions.
• Customer acquisition costs: Selling and marketing expense remained 27% above the prior-year level. The planned return to positive adjusted EBITDA depends partly on marketing reductions without undermining subscriber growth.
• Cash consumption: Quarterly operating cash flow turned negative, and cash declined during the first half. The debt-free balance sheet and undrawn revolver provide flexibility, but management’s forecast for cash growth depends on better profitability and recurring collections.
• New-product launch costs: The revised full-year outlook includes $2 million to $3 million of net XYOSTED launch costs, while the expected returns from that collaboration and other new channels remain dependent on second-half execution.

Summary

LifeMD’s Q2 showed progress in subscriber growth, pharmacy efficiency, and the transition to branded GLP-1 therapies, but those changes came with lower revenue, weaker upfront cash collection, and a wider loss. The central issue for the second half is whether longer subscriptions, reduced acquisition spending, and new pharmacy and partnership initiatives can deliver the profitability and cash-flow improvement embedded in the company’s Q3 and Q4 guidance.